Donald P Bottaro, PhD - Publications

Affiliations: 
1987- Urologic Oncology Branch National Cancer Institute, Rockville, MD, United States 
Area:
cancer biology, cancer genetics, cell and molecular biology
Website:
https://ccr.cancer.gov/urologic-oncology-branch/donald-p-bottaro

186 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Pahwa R, Dubhashi J, Singh A, Jailwala P, Lobanov A, Thomas CJ, Ceribelli M, Wilson K, Ricketts CJ, Vocke CD, Wells C, Bottaro DP, Linehan WM, Neckers L, Srinivasan R. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. Journal of Experimental & Clinical Cancer Research : Cr. 41: 208. PMID 35754026 DOI: 10.1186/s13046-022-02416-z  0.465
2021 Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, ... ... Bottaro DP, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 16: e0261994. PMID 34941969 DOI: 10.1371/journal.pone.0261994  0.741
2021 Lee YH, Lee MM, De Silva DM, Roy A, Wright CE, Wong TK, Costello R, Olaku O, Grubb RL, Agarwal PK, Apolo AB, Bottaro DP. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. Plos One. 16: e0241766. PMID 34292953 DOI: 10.1371/journal.pone.0241766  0.809
2021 Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, Park SR, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, et al. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs. PMID 34180036 DOI: 10.1007/s10637-021-01138-x  0.674
2020 Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, ... ... Bottaro DP, et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. The Lancet. Oncology. PMID 32645282 DOI: 10.1016/S1470-2045(20)30202-3  0.788
2019 Navas T, Kinders RJ, Lawrence SM, Ferry-Galow KV, Borgel S, Hollingshead MG, Srivastava AK, Alcoser SY, Makhlouf HR, Chuaqui R, Wilsker DF, Konaté MM, Miller SB, Voth AR, Chen L, ... ... Bottaro DP, et al. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Cancer Research. PMID 31732654 DOI: 10.1158/0008-5472.Can-18-3539  0.402
2019 Apolo AB, Mortazavi A, Hu ZI, Schonhoft J, Chu L, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara P, Stein MN, Steinberg SM, Mayfield C, Cordes LM, Mallek M, ... ... Bottaro DP, et al. Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi). Journal of Clinical Oncology. 37: 4555-4555. DOI: 10.1200/Jco.2019.37.15_Suppl.4555  0.313
2019 Navas T, Srivastava AK, Govindharajulu JP, Evrard YA, Borgel S, Carter J, Chen L, Das B, Divelbiss R, Karlovich C, Patidar R, Radzyminski M, Stottlemyer J, Williams PM, Hollingshead MG, ... Bottaro D, et al. Measuring phospho-MET by multiplex immunofluorescence to aid in selection of patients with MET activation in tumors. Journal of Clinical Oncology. 37: 3131-3131. DOI: 10.1200/Jco.2019.37.15_Suppl.3131  0.361
2018 Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, ... ... Bottaro DP, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer. PMID 30287223 DOI: 10.1016/J.Clgc.2018.09.005  0.468
2018 Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, et al. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. Plos One. 13: e0199361. PMID 29928062 DOI: 10.1371/Journal.Pone.0199361  0.537
2018 Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 3698. PMID 29925010 DOI: 10.1016/J.Celrep.2018.06.032  0.451
2018 Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 313-326.e5. PMID 29617669 DOI: 10.1016/J.Celrep.2018.03.075  0.502
2018 Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE. Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors. Molecular Cancer Therapeutics. PMID 29444985 DOI: 10.1158/1535-7163.Mct-17-0552  0.365
2018 Lee MM, Rabe DC, McKee TC, Woldemichael GM, Vasselli JR, McMahon JB, Linehan WM, Bottaro DP. Abstract A127: The identification and development of selective natural product inhibitors of hypoxia inducible factor-2α for the treatment of renal cell carcinoma Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A127  0.741
2018 Navas T, Srivastava AK, Ferry-Galow K, Makhlouf H, Chuaqui R, Kinders RJ, Bottaro DP, Chen AP, Parchment RE, Kummar S, Doroshow JH. Abstract A002: Evidence of pazopanib-induced epithelial-mesenchymal transition (EMT) in human tumors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A002  0.365
2017 De Silva DM, Roy A, Kato T, Cecchi F, Lee YH, Matsumoto K, Bottaro DP. Targeting the hepatocyte growth factor/Met pathway in cancer. Biochemical Society Transactions. PMID 28673936 DOI: 10.1042/Bst20160132  0.832
2017 Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE. Effective implementation of novel MET pharmacodynamic assays in translational studies. Annals of Translational Medicine. 5: 3. PMID 28164088 DOI: 10.21037/Atm.2016.12.78  0.36
2017 Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. HGF-MET in cancer progression and biomarker discovery. Cancer Science. PMID 28064454 DOI: 10.1111/Cas.13156  0.824
2017 Apolo AB, Mortazavi A, Stein MN, Pal SK, Davarpanah NN, Parnes HL, Ning YM, Francis DC, Cordes LM, Monk P, Lancaster T, Costello R, Nanda S, Bottaro DP, Wright JJ, et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Journal of Clinical Oncology. 35: 293-293. DOI: 10.1200/Jco.2017.35.6_Suppl.293  0.315
2017 Navas T, Hollingshead MG, Borgel S, Carter JP, Millione A, Gouker BA, Butcher D, Holbeck S, Srivastava AK, Kinders RJ, Bottaro DP, Kumar S, Chen A, Doroshow JH, Parchment RE. Abstract 845: A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics Cancer Research. 77: 845-845. DOI: 10.1158/1538-7445.Am2017-845  0.365
2017 Roy A, DeSilva DM, Bottaro DP. Abstract 5530: Evidence linking aquaporin-3 loss to increased invasiveness in bladder cancer Cancer Research. 77: 5530-5530. DOI: 10.1158/1538-7445.Am2017-5530  0.611
2016 Yau TC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, ... ... Bottaro DP, et al. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27821605 DOI: 10.1158/1078-0432.Ccr-16-1789  0.768
2016 Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma. Journal of Cancer. 7: 1205-14. PMID 27390595 DOI: 10.7150/Jca.14604  0.551
2016 Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Rabe DC, Gupta G, Choyke PL, Bottaro DP. Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer. Plos One. 11: e0157130. PMID 27300295 DOI: 10.1371/Journal.Pone.0157130  0.774
2016 Mungunsukh O, Lee YH, Bottaro DP, Day RM. The Hepatocyte Growth Factor Isoform NK2 Activates Motogenesis and Survival but not Proliferation due to Lack of Akt Activation. Cellular Signalling. PMID 27224506 DOI: 10.1016/J.Cellsig.2016.05.012  0.804
2016 Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders R, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, et al. Pharmacodynamic Response of the MET/HGF-Receptor to Small Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27001313 DOI: 10.1158/1078-0432.CCR-15-2323  0.445
2016 Chen F, Zhang Y, Şenbabaoğlu Y, Ciriello G, Yang L, Reznik E, Shuch B, Micevic G, De Velasco G, Shinbrot E, Noble MS, Lu Y, Covington KR, Xi L, Drummond JA, ... ... Bottaro DP, et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports. PMID 26947078 DOI: 10.1016/J.Celrep.2016.02.024  0.35
2016 Chu C, Bottaro DP, Betenbaugh MJ, Shiloach J. Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells. Plos One. 11: e0148075. PMID 26848584 DOI: 10.1371/Journal.Pone.0148075  0.448
2016 Srivastava AK, Govindharajulu JP, Park SR, Navas T, Ferry-Galow KV, Kinders RJ, Lee YH, Bottaro DP, Wright JJ, Hollingshead MG, Chen AP, Parchment RE, Kummar S, Doroshow JH. Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors. Journal of Clinical Oncology. 34: 2553-2553. DOI: 10.1200/Jco.2016.34.15_Suppl.2553  0.336
2016 Silva DD, Lee Y, Roy A, Bottaro DP. Abstract 4575: Altered catalytic properties of a subset of Met cytoplasmic domain variants occurring in renal cell carcinoma Cancer Research. 76: 4575-4575. DOI: 10.1158/1538-7445.Am2016-4575  0.75
2015 Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... ... Bottaro D, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917  0.476
2015 Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, Williams M, Wong KJ, Xu B, Szajek LP, Elbuluk O, Cecchi F, Raffensperger K, Golla M, Bottaro DP, et al. Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide. Molecular Imaging. 14: 499-515. PMID 26461980 DOI: 10.2310/7290.2015.00023  0.788
2015 Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Rabe DC, Cecchi F, Bottaro DP, LoRusso P. Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational New Drugs. PMID 26407571 DOI: 10.1007/S10637-015-0287-6  0.763
2015 Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program. Clinical & Experimental Metastasis. 32: 659-76. PMID 26231668 DOI: 10.1007/S10585-015-9735-0  0.829
2015 Bottaro DP, Lee YH, Wright CE, Wong TK, Agarwal PK, Apolo AB. Signaling by Met and related receptor tyrosine kinases in urothelial carcinoma of the bladder. Journal of Clinical Oncology. 33: e15511-e15511. DOI: 10.1200/Jco.2015.33.15_Suppl.E15511  0.594
2015 Albiges L, Murray B, Brooks A, Cherniack A, Berger A, Creighton CJ, Ricketts C, Bottaro DP, Srinivasan R, Schmidt LS, Meyerson M, Spellman P, Linehan WM, Choueiri TK. Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. Journal of Clinical Oncology. 33: 4521-4521. DOI: 10.1200/Jco.2015.33.15_Suppl.4521  0.509
2015 Navas T, Pfister TD, Lawrence SM, Srivastava AK, Kinders RJ, Borgel S, Alcoser S, Hollingshead MG, Dutko LM, Gouker BA, Butcher D, Ng-Eaton E, Takebe N, Lee YH, Bottaro DP, et al. Abstract 5082: Impact of HGF knockin microenvironment on epithelial-mesenchymal transition and cancer stem cells in a non-small cell lung cancer xenograft model Cancer Research. 75: 5082-5082. DOI: 10.1158/1538-7445.Am2015-5082  0.545
2015 Lee YH, Wong TK, Apolo AB, Agarwal PK, Bottaro DP. Abstract 140: Oncogenic signaling by MET and other cabozantinib targets in cells derived from urothelial carcinoma of the bladder Cancer Research. 75: 140-140. DOI: 10.1158/1538-7445.Am2015-140  0.603
2015 Navas T, Kinders RJ, Lawrence SM, Ferry-Galow K, Pfister TD, Srivastava AK, Alcoser SY, Hollingshead MG, Dutko LM, Gouker BA, Butcher DO, Makhlouf H, Chuaqui R, Bottaro DP, Kummar S, et al. Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B18  0.333
2015 Kaye DR, Pinto PA, Cecchi F, Reilly J, Semerjian A, Giubellino A, Gupta G, Choyke PL, Linehan WM, Bottaro DP. MP6-17 PREDICTIVE VALUE OF PLASMA SOLUBLE MET PROTEIN CONCENTRATION IN PATIENTS WITH PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.264  0.771
2015 Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program Clinical and Experimental Metastasis. DOI: 10.1007/s10585-015-9735-0  0.713
2014 Apolo AB, Bottaro DP, Merino MJ, Xi L, Lee YH, Weinberg BA, Wright JJ, Dahut WL, Parnes HL, Raffeld M. 811PDMET TUMOR EXPRESSION AND MUTATIONAL ANALYSIS IN BLADDER CANCER PATIENTS (PTS) RECEIVING CABOZANTINIB. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv281. PMID 28170949 DOI: 10.1093/annonc/mdu337.4  0.429
2014 Lee YH, Apolo AB, Agarwal PK, Bottaro DP. Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. Cancers. 6: 2313-29. PMID 25534569 DOI: 10.3390/Cancers6042313  0.596
2014 McNeil BK, Sorbellini M, Grubb RL, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, ... ... Bottaro DP, et al. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine. 12: 199. PMID 25335552 DOI: 10.1186/1479-5876-12-199  0.801
2014 Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews. Urology. 11: 465-75. PMID 25048860 DOI: 10.1038/Nrurol.2014.162  0.521
2014 Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, et al. Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. Plos One. 9: e100586. PMID 24983965 DOI: 10.1371/Journal.Pone.0100586  0.634
2014 Lee YH, Morrison BL, Bottaro DP. Synergistic signaling of tumor cell invasiveness by Hepatocyte growth factor and hypoxia Journal of Biological Chemistry. 289: 20448-20461. PMID 24914205 DOI: 10.1074/Jbc.M114.580597  0.611
2014 Hembrough TA, Liao W, Thyparambil S, Henderson L, Rambo B, Cecchi F, Bottaro DP, Darfler M, Xu P, Xiao S, Zhao L, Veenstra TD, Burrows J, Catenacci DVT. Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue. Journal of Clinical Oncology. 32: 16-16. DOI: 10.1200/Jco.2014.32.3_Suppl.16  0.59
2014 Bottaro DP, Lee YH, Agarwal PK, Apolo AB. Met signaling in urothelial carcinoma of the bladder. Journal of Clinical Oncology. 32: 4551-4551. DOI: 10.1200/Jco.2014.32.15_Suppl.4551  0.605
2014 Apolo AB, Tomita Y, Lee M, Lee S, Frosch A, Steinberg SM, Gulley JL, Schlom J, Bottaro DP, Trepel JB. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. Journal of Clinical Oncology. 32: 4501-4501. DOI: 10.1200/Jco.2014.32.15_Suppl.4501  0.331
2014 Cecchi F, Lih J, Lee Y, Walsh W, Williams M, Bottaro DP. Abstract 5259: Gene expression array and pathway profiling analyses distinguish HGF/Met pathways driving cell proliferation from invasion and identify events correlated with prostate cancer progression Cancer Research. 74: 5259-5259. DOI: 10.1158/1538-7445.Am2014-5259  0.735
2014 Lee YH, Bottaro DP. Abstract 489: Hypoxia-mediated ROS enhances HGF-induced cancer cell invasion and suppresses cell cycle progression Cancer Research. 74: 489-489. DOI: 10.1158/1538-7445.Am2014-489  0.608
2014 Lee YH, Apolo A, Agarwal PK, Bottaro DP. Abstract 4670: Characterization of Met signaling in urothelial cancer of the bladder Cancer Research. 74: 4670-4670. DOI: 10.1158/1538-7445.Am2014-4670  0.6
2014 Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Peggins J, Bottaro DP, Wright JJ, Kinders RJ, Tomaszewski JE, Doroshow JH, Parchment RE. Abstract 3691: Met target inhibition-guided efficacy in preclinical models Cancer Research. 74: 3691-3691. DOI: 10.1158/1538-7445.Am2014-3691  0.334
2014 Navas T, Lawrence SL, Butcher D, Dutko LM, Hollingshead MG, Kinders RJ, Parchment RE, Bottaro DP, Linehan WM, Tomaszewski JE, Srivastava AK, Doroshow JH. Abstract 1049: Quantitative immunofluorescence assessment of MET and epithelial to mesenchymal transition (EMT) biomarker modulation by antiangiogenic inhibitors in xenograft tumor tissues Cancer Research. 74: 1049-1049. DOI: 10.1158/1538-7445.Am2014-1049  0.525
2014 Cecchi F, Liao W, Thyparambil S, Bengali K, Uzzell J, Darflar M, Krizman D, Burrows J, Hembrough T, Veenstra T, Bottaro D, Karrison T, Henderson L, Xu P, Rambo B, et al. 537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue European Journal of Cancer. 50: 175. DOI: 10.1016/S0959-8049(14)70663-X  0.581
2013 Lee YH, Cecchi F, Agarwal PK, Parnes HL, Khadar K, Summerell A, Gulley JL, Compton K, Figg WD, Dahut WL, Bottaro DP. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314. PMID 28136967 DOI: 10.1200/Jco.2013.31.15_Suppl.4543  0.732
2013 Zhang M, Luo Z, Liu H, Croce CM, Burke TR, Bottaro DP. Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist. Leukemia. 28: 948-51. PMID 24172825 DOI: 10.1038/Leu.2013.323  0.301
2013 Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, ... ... Bottaro DP, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Plos One. 8: e54014. PMID 23516391 DOI: 10.1371/Journal.Pone.0054014  0.782
2013 Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, ... ... Bottaro DP, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 181-6. PMID 23213094 DOI: 10.1200/Jco.2012.43.3383  0.508
2013 Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, ... ... Bottaro DP, et al. Patient enrollment and participation flow chart. Plos One. DOI: 10.1371/Journal.Pone.0054014.G001  0.726
2013 Apolo AB, Parnes HL, Madan RA, Gulley JL, Wright JJ, Khadar K, Trepel JB, Schlom J, Arlen PM, Merino M, Steinberg SM, Choyke PL, Lindenberg ML, Kurdziel KA, Folio L, ... ... Bottaro DP, et al. A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. Journal of Clinical Oncology. 31: TPS4589-TPS4589. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps4589  0.387
2013 Apolo AB, Lee YH, Cecchi F, Agarwal PK, Parnes HL, Khadar K, Summerell A, Gulley JL, Compton K, Figg WD, Dahut WL, Bottaro DP. Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC). Journal of Clinical Oncology. 31: 4543-4543. DOI: 10.1200/JCO.2013.31.15_SUPPL.4543  0.303
2013 Srivastava AK, Hollingshead MG, Weiner J, Covey JM, Liston D, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Tomaszewski JE, Parchment RE, Doroshow JH. Application of MET pharmacodynamic assays to compare effectiveness of five MET inhibitors to engage target in tumor tissue. Journal of Clinical Oncology. 31: 11103-11103. DOI: 10.1200/Jco.2013.31.15_Suppl.11103  0.351
2013 Wright CE, Jagoda E, Cecchi F, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Lang L, Szajek L, Paik C, Choyke PL, Marik J, Tinianow J, ... ... Bottaro DP, et al. Developing a molecular imaging agent for Met using onartuzumab (MetMAb). Journal of Clinical Oncology. 31: 11083-11083. DOI: 10.1200/Jco.2013.31.15_Suppl.11083  0.629
2013 Cecchi F, Rex K, Schmidt J, Baker D, Damore MA, Coxon A, Burgess TL, Bottaro DP. Abstract 5637: A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma. Cancer Research. 73: 5637-5637. DOI: 10.1158/1538-7445.Am2013-5637  0.678
2013 Lee YH, Bottaro DP. Abstract 4285: Hypoxia-mediated autophagy enhances HGF-induced cancer cell invasion. Cancer Research. 73: 4285-4285. DOI: 10.1158/1538-7445.Am2013-4285  0.608
2013 Cecchi F, Lih C, Lee YH, Walsh WD, Williams MP, Bottaro DP. Abstract 4085: Experimental metastasis by the prostate adenocarcinoma-derived cell line PC3M is driven by partial activation of the human Met pathway. Cancer Research. 73: 4085-4085. DOI: 10.1158/1538-7445.Am2013-4085  0.732
2013 Chan S, Popplewell W, Henrich C, Linehan W, Bottaro D, McMahon J, McKee T, Gustafson K. Isolation and Identification of Natural Products from Artocarpus communis Planta Medica. 79. DOI: 10.1055/S-0033-1348739  0.37
2012 Srinivasan R, Bottaro DP, Choueiri TK, Vaishampayan UN, Rosenberg JE, Logan T, Harzstark AL, Rini BI, Srinivas S, Adams LM, Laubscher K, Ottesen LH, McDermott DF, Linehan WM. Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 372. PMID 27968180 DOI: 10.1200/Jco.2012.30.5_Suppl.372  0.513
2012 Choueiri TK, Vaishampayan UN, Rosenberg JE, Logan T, Harzstark AL, Rini BI, Srinivas S, Adams LM, Sherman LJ, Ottesen LH, McDermott DF, Bottaro DP, Linehan WM, Srinivasan R. A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 355. PMID 27967970 DOI: 10.1200/Jco.2012.30.5_Suppl.355  0.513
2012 Cecchi F, Bottaro DP. Novel antagonists of heparin binding growth factors. Oncotarget. 3: 911-2. PMID 22989865 DOI: 10.18632/Oncotarget.645  0.631
2012 McKee TC, Rabe D, Bokesch HR, Grkovic T, Whitson EL, Diyabalanage T, Van Wyk AW, Marcum SR, Gardella RS, Gustafson KR, Linehan WM, McMahon JB, Bottaro DP. Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges. Journal of Natural Products. 75: 1632-6. PMID 22928967 DOI: 10.1021/Np300211X  0.732
2012 Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, ... ... Bottaro DP, et al. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1592-600. PMID 22917884 DOI: 10.2967/Jnumed.111.102293  0.803
2012 Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. Plos One. 7: e42717. PMID 22912725 DOI: 10.1371/Journal.Pone.0042717  0.39
2012 Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP. Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell. 22: 250-62. PMID 22897854 DOI: 10.1016/J.Ccr.2012.06.029  0.812
2012 Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opinion On Therapeutic Targets. 16: 553-72. PMID 22530990 DOI: 10.1517/14728222.2012.680957  0.815
2012 Athauda G, Cecchi F, Ito T, Giubellino A, Rabe D, Raffensperger K, Lee Y, Bottaro D. HGF (hepatocyte growth factor (hepapoietin A; scatter factor)) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/46082  0.728
2012 Lee YH, Bottaro DP. Abstract 1225: Integration of HGF/Met signaling and hypoxia response in cancer cell invasion and proliferation Cancer Research. 72: 1225-1225. DOI: 10.1158/1538-7445.Am2012-1225  0.618
2012 Kauffman E, Gupta G, Cecchi F, Raffensperger K, Linehan WM, Bottaro DP, Srinivasan R. 448 CHARACTERIZATION OF THE AKT-MTOR PATHWAY IN TFE3-FUSION RENAL CELL CANCERS AND IMPLICATIONS FOR TARGETED THERAPY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.515  0.789
2012 Sorbellini M, McNeil B, Giubellino A, Dharmawardana G, Simpson H, Coleman J, Getzenberg R, Netto G, Pinto P, Linehan M, Bottaro D. 1283 URINARY MET LEVEL AS A NOVEL BIOMARKER FOR UROTHELIAL CARCINOMA OF THE BLADDER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1615  0.77
2012 Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC. ChemInform Abstract: A New Hypoxia Inducible Factor-2 Inhibitory Pyrrolinone Alkaloid from Roots and Stems of Piper sarmentosum. Cheminform. 43: no-no. DOI: 10.1002/CHIN.201208208  0.634
2011 Srivastava AK, Hollingshead MG, Weiner J, Khin S, Borgel S, Risbood P, Pfister TD, Lawrence SM, Kinders RJ, Bottaro DP, Tomaszewski JE, Parchment RE, Doroshow JH. Development and validation of biomarker assays to assess pharmacodynamic modulation of MET. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3042. PMID 28022620 DOI: 10.1200/Jco.2011.29.15_Suppl.3042  0.395
2011 Merchant M, Marik J, Peng J, Williams SP, Ogasawara A, Tinianow JN, Bhadrasetty V, Lang L, Lee SM, Kim I, Williams M, Szajek L, Raffensperger KE, Cecchi F, Jagoda E, ... ... Bottaro DP, et al. Proof of concept of immuno-PET molecular imaging of met using (76)Br- and (89)Zr-labeled MetMAb. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10632. PMID 28022451 DOI: 10.1200/Jco.2011.29.15_Suppl.10632  0.668
2011 Cecchi F, Pajalunga D, Fowler A, Rabe DC, Peruzzi B, MacDonald NJ, Blackman DK, Stahl SJ, Byrd A, Bottaro DP. A hepatocyte growth factor antagonist engineered by site-directed mutagenesis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10528. PMID 28021761 DOI: 10.1200/Jco.2011.29.15_Suppl.10528  0.802
2011 Sorbellini M, Giubellino A, Srivastava G, Sourbier C, Pinto PA, Linehan W, Bottaro DP. Effect of the orally available MET inhibitor PF-2341066 on tumor burden and metastasis in an orthotopic xenograft model of bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 263. PMID 27968590 DOI: 10.1200/Jco.2011.29.7_Suppl.263  0.73
2011 Sorbellini M, Giubellino A, Srivastava G, Sourbier C, Jagoda E, Williams M, Choyke PL, Pinto PA, Linehan W, Bottaro DP. Use of a MET-specific photoprobe to identify bladder tumors in an orthotopic xenograft model of bladder cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 260. PMID 27968576 DOI: 10.1200/Jco.2011.29.7_Suppl.260  0.723
2011 Sorbellini M, McNeil B, Cohen B, Athauda G, Giubellino A, Coleman J, Netto GJ, Getzenberg RH, Linehan W, Bottaro DP. Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 257. PMID 27968502 DOI: 10.1200/Jco.2011.29.7_Suppl.257  0.795
2011 Cecchi F, Rabe DC, Bottaro DP. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. Current Signal Transduction Therapy. 6: 146-151. PMID 25197268 DOI: 10.2174/157436211795659955  0.823
2011 Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. Chemical & Pharmaceutical Bulletin. 59: 1178-9. PMID 21881266 DOI: 10.1248/Cpb.59.1178  0.702
2011 Liu F, Giubellino A, Simister PC, Qian W, Giano MC, Feller SM, Bottaro DP, Burke TR. Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides. Biopolymers. 96: 780-8. PMID 21830199 DOI: 10.1002/Bip.21692  0.635
2011 Grkovic T, Whitson EL, Rabe DC, Gardella RS, Bottaro DP, Linehan WM, McMahon JB, Gustafson KR, McKee TC. Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression. Bioorganic & Medicinal Chemistry Letters. 21: 2113-5. PMID 21353547 DOI: 10.1016/J.Bmcl.2011.01.127  0.732
2011 Cecchi F, Rex K, Schmidt J, Baker D, Damore MA, Coxon A, Burgess TL, Bottaro DP. Abstract A204: A cellular model of acquired resistance to rilotumumab (AMG 102) in glioblastoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A204  0.687
2010 Mungunsukh O, Lee YH, Marquez AP, Cecchi F, Bottaro DP, Day RM. A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation. American Journal of Physiology. Lung Cellular and Molecular Physiology. 299: L905-14. PMID 20889677 DOI: 10.1152/Ajplung.00094.2010  0.809
2010 Felici A, Giubellino A, Bottaro DP. Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells. Journal of Cellular Biochemistry. 111: 310-21. PMID 20506405 DOI: 10.1002/Jcb.22695  0.714
2010 Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. European Journal of Cancer (Oxford, England : 1990). 46: 1260-70. PMID 20303741 DOI: 10.1016/J.Ejca.2010.02.028  0.816
2010 Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R. Molecular diagnosis and therapy of kidney cancer. Annual Review of Medicine. 61: 329-43. PMID 20059341 DOI: 10.1146/Annurev.Med.042808.171650  0.513
2010 Sorbellini M, McNeil B, Simpson H, Giubellino A, Hsieh T, Getzenberg RH, Schoenberg M, Gagani C, Bottaro DP. Correlation of Met expression in TCC of the bladder with stage and grade. Journal of Clinical Oncology. 28: e15110-e15110. DOI: 10.1200/Jco.2010.28.15_Suppl.E15110  0.649
2010 Cecchi F, Pajalunga D, McNeil B, Rabe D, Fowler A, Liu Y, Gagnon CR, Kallender H, Shah MA, Getzenberg R, Schoenberg M, Martin A, Srinivasan R, Linehan WM, Byrd RA, ... Bottaro DP, et al. Abstract SY23-03: Oncogenic signal transduction via the hepatocyte growth factor/Met receptor kinase pathway Cellular and Molecular Biology. DOI: 10.1158/1538-7445.Am10-Sy23-03  0.805
2010 Rabe DC, McKee T, Woldemichael GM, Vasselli JR, McMahon J, Linehan WM, Bottaro DP. Abstract 773: Identification and characterization of natural product-based inhibitors of hypoxia inducible factor-2 alpha Cancer Research. 70: 773-773. DOI: 10.1158/1538-7445.Am10-773  0.768
2010 Cecchi F, Pajalunga D, Rabe DC, Peruzzi B, Fowler AC, Blackman DK, MacDonald N, Stahl SJ, Byrd AR, Bottaro DP. Abstract 342: A hepatocyte growth factor antagonist engineered by disruption of heparan sulfate binding Cancer Research. 70: 342-342. DOI: 10.1158/1538-7445.Am10-342  0.811
2010 Niswander LM, Guenther LM, Cecchi F, Giubellino A, Bottaro DP, Christensen JG, Khanna C, Helman LJ, Kim SY. Abstract 3401: Genetic down-regulation of MET alters the metastatic phenotype of osteosarcoma cells Cancer Research. 70: 3401-3401. DOI: 10.1158/1538-7445.Am10-3401  0.788
2009 Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer Clinical Cancer Research. 15: 4292-4298. PMID 19549766 DOI: 10.1158/1078-0432.Ccr-09-0599  0.33
2009 Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer Expert Review of Anticancer Therapy. 9: 785-793. PMID 19496715 DOI: 10.1586/Era.09.43  0.725
2009 Linehan WM, Pinto PA, Bratslavsky G, Pfaffenroth E, Merino M, Vocke CD, Toro JR, Bottaro D, Neckers L, Schmidt LS, Srinivasan R. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer. 115: 2252-61. PMID 19402075 DOI: 10.1002/Cncr.24230  0.531
2009 Choi WJ, Kim SE, Stephen AG, Weidlich I, Giubellino A, Liu F, Worthy KM, Bindu L, Fivash MJ, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR. Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids. Journal of Medicinal Chemistry. 52: 1612-8. PMID 19226165 DOI: 10.1021/Jm800789H  0.633
2009 Peach ML, Tan N, Choyke SJ, Giubellino A, Athauda G, Burke TR, Nicklaus MC, Bottaro DP. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. Journal of Medicinal Chemistry. 52: 943-51. PMID 19199650 DOI: 10.1021/Jm800791F  0.804
2009 Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. The International Journal of Biochemistry & Cell Biology. 41: 753-6. PMID 18950731 DOI: 10.1016/J.Biocel.2008.09.024  0.528
2009 Cecchi F, Pajalunga D, Rabe D, Fowler AC, MacDonald N, Blackman DK, Stahl SJ, Byrd AR, Bottaro DP. Abstract B228: A hepatocyte growth factor antagonist engineered by targeted disruption of heparan sulfate binding Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B228  0.813
2009 Cecchi F, Liu Y, Gagnon RC, Kallender H, Rabe DC, Shah MA, Martin A, Bottaro DP. Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B210  0.758
2009 LoRusso P, Eder JP, Sherman L, McCallum S, Liu Y, Bottaro D, Cecchi F, Rabe D, Miles D, Shapiro G. Abstract A8: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A8  0.757
2009 Giubellino A, Liu F, Burke T, Bottaro DP. Abstract A163: Development of Grb2 SH3 domain antagonists Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A163  0.708
2008 Giubellino A, Shi ZD, Jenkins LM, Worthy KM, Bindu LK, Athauda G, Peruzzi B, Fisher RJ, Appella E, Burke TR, Bottaro DP. Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist. Journal of Medicinal Chemistry. 51: 7459-68. PMID 18989951 DOI: 10.1021/Jm800523U  0.807
2008 Giubellino A, Burke TR, Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opinion On Therapeutic Targets. 12: 1021-33. PMID 18620523 DOI: 10.1517/14728222.12.8.1021  0.678
2008 Lee SJ, Lattouf JB, Xanthopoulos J, Linehan WM, Bottaro DP, Vasselli JR. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. European Urology. 54: 845-53. PMID 18243508 DOI: 10.1016/J.Eururo.2008.01.010  0.574
2008 Athauda G, Bottaro DP. GRB2 (Growth factor receptor-bound protein 2) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/16961  0.742
2008 Bottaro DP, Tan N, Linehan WM. Regulation of angiogenesis by von Hippel Lindau protein and HIF2 Angiogenesis: An Integrative Approach From Science to Medicine. 181-191. DOI: 10.1007/978-0-387-71518-6_16  0.697
2007 Rubin JS, Bottaro DP. Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4660-3. PMID 17699841 DOI: 10.1158/1078-0432.Ccr-07-1077  0.366
2007 Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR, Bottaro DP. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Research. 67: 6012-6. PMID 17616655 DOI: 10.1158/0008-5472.Can-07-0022  0.729
2007 Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 671s-679s. PMID 17255292 DOI: 10.1158/1078-0432.Ccr-06-1870  0.49
2007 Liu F, Worthy KM, Bindu L, Giubellino A, Bottaro DP, Fisher RJ, Burke TR. Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis. Organic & Biomolecular Chemistry. 5: 367-72. PMID 17205182 DOI: 10.1039/B611887A  0.636
2006 Peruzzi B, Bottaro DP. Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. Cell Cycle (Georgetown, Tex.). 5: 2839-41. PMID 17218789 DOI: 10.4161/Cc.5.24.3581  0.719
2006 Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 14531-6. PMID 16983094 DOI: 10.1073/Pnas.0606850103  0.805
2006 Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP. c-Met ectodomain shedding rate correlates with malignant potential. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4154-62. PMID 16857786 DOI: 10.1158/1078-0432.Ccr-06-0250  0.827
2006 Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3657-60. PMID 16778093 DOI: 10.1158/Aacr.Edb-Ccr-06-0818  0.764
2006 Dharmawardana PG, Peruzzi B, Giubellino A, Burke TR, Bottaro DP. Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anti-Cancer Drugs. 17: 13-20. PMID 16317285 DOI: 10.1097/01.Cad.0000185180.72604.Ac  0.832
2005 Bottaro DP, Linehan WM. Multifocal renal cancer: Genetic basis and its medical relevance Clinical Cancer Research. 11: 7206-7208. PMID 16243789 DOI: 10.1158/1078-0432.Ccr-05-1343  0.44
2005 Kang SU, Shi ZD, Worthy KM, Bindu LK, Dharmawardana PG, Choyke SJ, Bottaro DP, Fisher RJ, Burke TR. Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. Journal of Medicinal Chemistry. 48: 3945-8. PMID 15943469 DOI: 10.1021/Jm050059M  0.781
2005 Salazar K, Bottaro D, Vasselli J, Neckers L, Linehan WM, Coleman J. 585: Targeted Drug Therapies and Cellular Response in Human Bladder Cancer Cell Lines Journal of Urology. 173: 160-160. DOI: 10.1016/S0022-5347(18)34825-0  0.482
2004 Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Current Molecular Medicine. 4: 855-68. PMID 15579033 DOI: 10.2174/1566524043359674  0.703
2004 Soriano JV, Liu N, Gao Y, Yao ZJ, Ishibashi T, Underhill C, Burke TR, Bottaro DP. Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Molecular Cancer Therapeutics. 3: 1289-99. PMID 15486196  0.784
2004 Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L, Figlin R, et al. Genetic basis of cancer of the kidney: Disease-specific approaches to therapy Clinical Cancer Research. 10: 6282s-6289s. PMID 15448018 DOI: 10.1158/1078-0432.Ccr-050013  0.542
2004 Ruggiero M, Bottaro DP, Liguri G, Gulisano M, Peruzzi B, Pacini S. 0.2 T magnetic field inhibits angiogenesis in chick embryo chorioallantoic membrane. Bioelectromagnetics. 25: 390-6. PMID 15197764 DOI: 10.1002/Bem.20008  0.668
2004 Williams CR, Neckers LM, Bottaro DP, Coleman JA. 975: The HSP90 Inhibitor 17-Desmethoxy-17-N, N-Dimethylaminoethylamino-Geldanamycin (17-DMAG) Downregulates Expression of C-MET and Akt and Phospho-Akt Proteins in T24 Bladder Cancer Cells Journal of Urology. 171: 258-258. DOI: 10.1016/S0022-5347(18)38212-0  0.342
2002 Ishimoto S, Ishibashi T, Bottaro DP, Kaga K. Direct application of keratinocyte growth factor, basic fibroblast growth factor and transforming growth factor-alpha during healing of tympanic membrane perforation in glucocorticoid-treated rats. Acta Oto-Laryngologica. 122: 468-73. PMID 12206253 DOI: 10.1080/00016480260092246  0.329
2002 Bottaro DP. The role of extracellular matrix heparan sulfate glycosaminoglycan in the activation of growth factor signaling pathways. Annals of the New York Academy of Sciences. 961: 158. PMID 12081887 DOI: 10.1111/J.1749-6632.2002.Tb03071.X  0.349
2002 Bottaro DP, Liebmann-Vinson A, Heidaran MA. Molecular signaling in bioengineered tissue microenvironments. Annals of the New York Academy of Sciences. 961: 143-53. PMID 12081884 DOI: 10.1111/J.1749-6632.2002.Tb03068.X  0.31
2002 Day RM, Soon L, Breckenridge D, Bridges B, Patel BK, Wang LM, Corey SJ, Bottaro DP. Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene. 21: 2201-11. PMID 11948403 DOI: 10.1038/Sj.Onc.1205289  0.748
2002 Jian Li Z, Zhao Q, Liang H, Jiang S, Chen T, Grella D, Shearon C, Bottaro DP, Sim BKL. Biotechnology Letters. 24: 1631-1635. DOI: 10.1023/A:1020357732474  0.331
2001 Rubin JS, Day RM, Breckenridge D, Atabey N, Taylor WG, Stahl SJ, Wingfield PT, Kaufman JD, Schwall R, Bottaro DP. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. The Journal of Biological Chemistry. 276: 32977-83. PMID 11435444 DOI: 10.1074/Jbc.M105486200  0.782
2001 Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV, Burke TR, Bottaro DP. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. The Journal of Biological Chemistry. 276: 14308-14. PMID 11278639 DOI: 10.1074/Jbc.M010202200  0.802
2001 Reboul P, Pelletier J, Tardif G, Benderdour M, Ranger P, Bottaro DP, Martel-Pelletier J. Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: Involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade Arthritis & Rheumatism. 44: 73-84. DOI: 10.1002/1529-0131(200101)44:1<73::Aid-Anr11>3.0.Co;2-E  0.375
2000 Nekhai S, Bottaro DP, Woldehawariat G, Spellerberg A, Petryshyn R. A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation. Peptides. 21: 1449-1456. PMID 11068090 DOI: 10.1016/S0196-9781(00)00297-7  0.331
2000 Bies J, Feiková S, Bottaro DP, Wolff L. Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases Oncogene. 19: 2846-2854. PMID 10851088 DOI: 10.1038/Sj.Onc.1203613  0.32
2000 Castagnino P, Lorenzi MV, Yeh J, Breckenridge D, Sakata H, Munz B, Werner S, Bottaro DP. Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. Oncogene. 19: 640-8. PMID 10698509 DOI: 10.1038/Sj.Onc.1203357  0.797
2000 Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, Cumberledge S, Rubin JS. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. The Journal of Biological Chemistry. 275: 4374-82. PMID 10660608 DOI: 10.1074/Jbc.275.6.4374  0.33
2000 Sakaguchi K, Lorenzi MV, Bottaro DP, Miki T. The acidic domain and first immunoglobulin-like loop of fibroblast growth factor receptor 2 modulate downstream signaling through glycosaminoglycan modification. Molecular and Cellular Biology. 19: 6754-64. PMID 10490614 DOI: 10.1128/Mcb.19.10.6754  0.415
2000 Otsuka T, Jakubczak J, Vieira W, Bottaro DP, Breckenridge D, Larochelle WJ, Merlino G. Disassociation of Met-Mediated Biological Responses In Vivo: the Natural Hepatocyte Growth Factor/Scatter Factor Splice Variant NK2 Antagonizes Growth but Facilitates Metastasis Molecular and Cellular Biology. 20: 2055-2065. DOI: 10.1128/Mcb.20.6.2055-2065.2000  0.375
1999 Zhou H, Casas-Finet JR, Heath Coats R, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA. Identification and dynamics of a heparin-binding site in hepatocyte growth factor. Biochemistry. 38: 14793-802. PMID 10555961 DOI: 10.1021/Bi9908641  0.571
1999 Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. The Journal of Biological Chemistry. 274: 19465-72. PMID 10383463 DOI: 10.1074/Jbc.274.27.19465  0.625
1999 Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene. 18: 3399-406. PMID 10362361 DOI: 10.1038/Sj.Onc.1202683  0.799
1999 LaRochelle WJ, Sakaguchi K, Atabey N, Cheon HG, Takagi Y, Kinaia T, Day RM, Miki T, Burgess WH, Bottaro DP. Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. Biochemistry. 38: 1765-71. PMID 10026256 DOI: 10.1021/Bi982092Z  0.771
1998 Kim PJ, Sakaguchi K, Sakamoto H, Saxinger C, Day R, McPhie P, Rubin JS, Bottaro DP. Colocalization of heparin and receptor binding sites on keratinocyte growth factor. Biochemistry. 37: 8853-62. PMID 9636026 DOI: 10.1021/Bi9801917  0.8
1998 de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes & Development. 12: 1587-92. PMID 9620846 DOI: 10.1101/Gad.12.11.1587  0.736
1998 Zhou H, Mazzulla MJ, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA. The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site. Structure (London, England : 1993). 6: 109-16. PMID 9493272 DOI: 10.1016/S0969-2126(98)00012-4  0.65
1998 Castagnino P, Soriano JV, Montesano R, Bottaro DP. Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor Oncogene. 17: 481-492. DOI: 10.1038/Sj.Onc.1201957  0.787
1997 Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. The Embo Journal. 16: 5608-17. PMID 9312020 DOI: 10.1093/Emboj/16.18.5608  0.353
1997 Stahl SJ, Wingfield PT, Kaufman JD, Pannell LK, Cioce V, Sakata H, Taylor WG, Rubin JS, Bottaro DP. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. The Biochemical Journal. 326: 763-72. PMID 9307026 DOI: 10.1042/Bj3260763  0.799
1997 Shin DY, Ishibashi T, Choi TS, Chung E, Chung IY, Aaronson SA, Bottaro DP. A novel human ERK phosphatase regulates H-ras and v-raf signal transduction. Oncogene. 14: 2633-9. PMID 9178761 DOI: 10.1038/Sj.Onc.1201106  0.582
1996 Wadsworth P, Bottaro DP. Microtubule dynamic turnover is suppressed during polarization and stimulated in hepatocyte growth factor scattered Madin-Darby canine kidney epithelial cells. Cell Motility and the Cytoskeleton. 35: 225-36. PMID 8913643 DOI: 10.1002/(Sici)1097-0169(1996)35:3<225::Aid-Cm5>3.0.Co;2-7  0.305
1996 Li W, Chen XH, Kelley CA, Alimandi M, Zhang J, Chen Q, Bottaro DP, Pierce JH. Identification of tyrosine 187 as a protein kinase C-delta phosphorylation site. The Journal of Biological Chemistry. 271: 26404-9. PMID 8824297 DOI: 10.1074/jbc.271.42.26404  0.725
1996 Nekhai S, Kumar A, Bottaro DP, Petryshyn R. Peptides Derived from the Interferon-Induced PKR Prevent Activation by HIV-1 TAR RNA Virology. 222: 193-200. PMID 8806499 DOI: 10.1006/Viro.1996.0410  0.307
1996 Cioce V, Csaky KG, Chan AM, Bottaro DP, Taylor WG, Jensen R, Aaronson SA, Rubin JS. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. The Journal of Biological Chemistry. 271: 13110-5. PMID 8662798 DOI: 10.1074/Jbc.271.22.13110  0.81
1995 Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cunha GR, Finch PW. Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction Exs. 74: 191-214. PMID 8527895 DOI: 10.1007/978-3-0348-9070-0_10  0.338
1995 Santoro M, Carlomagno F, Romano A, Bottaro D, Dathan N, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus M. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B Science. 267: 381-383. PMID 7824936 DOI: 10.1126/Science.7824936  0.318
1995 Aroca P, Bottaro DP, Ishibashi T, Aaronson SA, Santos E. Human dual specificity phosphatase VHR activates maturation promotion factor and triggers meiotic maturation in Xenopus oocytes. The Journal of Biological Chemistry. 270: 14229-34. PMID 7775484 DOI: 10.1074/Jbc.270.23.14229  0.593
1994 Cheon HG, LaRochelle WJ, Bottaro DP, Burgess WH, Aaronson SA. High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains. Proceedings of the National Academy of Sciences of the United States of America. 91: 989-93. PMID 8302878 DOI: 10.1073/Pnas.91.3.989  0.611
1994 Adams DH, Harvath L, Bottaro DP, Interrante R, Catalano G, Tanaka Y, Strain A, Hubscher SG, Shaw S. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proceedings of the National Academy of Sciences of the United States of America. 91: 7144-8. PMID 8041760 DOI: 10.1073/Pnas.91.15.7144  0.356
1994 Ishibashi T, Bottaro D, Michieli P, Kelley CA, Aaronson SA. A novel dual specificity phosphatase induced by serum stimulation and heat shock. Journal of Biological Chemistry. 269: 29897-29902. DOI: 10.1016/s0021-9258(18)43965-8  0.68
1993 Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product Bba - Reviews On Cancer. 1155: 357-371. PMID 8268192 DOI: 10.1016/0304-419X(93)90015-5  0.603
1993 Ishibashi T, Bottaro DP, Chan A, Miki T, Aaronson SA. Expression cloning of a human dual-specificity phosphatase. Proceedings of the National Academy of Sciences of the United States of America. 89: 12170-4. PMID 1281549 DOI: 10.1073/Pnas.89.24.12170  0.632
1992 Molloy CJ, Fleming TP, Bottaro DP, Cuadrado A, Aaronson SA. Platelet-derived growth factor stimulation of GTPase-activating protein tyrosine phosphorylation in control and c-H-ras-expressing NIH 3T3 cells correlates with p21ras activation. Molecular and Cellular Biology. 12: 3903-9. PMID 1508192 DOI: 10.1128/Mcb.12.9.3903  0.615
1992 Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proceedings of the National Academy of Sciences of the United States of America. 89: 246-50. PMID 1309608 DOI: 10.1073/Pnas.89.1.246  0.625
1992 Di Fiore P, Helin K, Kraus M, Pierce J, Artrip J, Segatto O, Bottaro D. A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185erbB-2. The Embo Journal. 11: 3927-3933. DOI: 10.1002/J.1460-2075.1992.Tb05486.X  0.409
1991 Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (New York, N.Y.). 251: 802-4. PMID 1846706 DOI: 10.1126/Science.1846706  0.631
1991 Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA. Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop Science. 251: 72-75. PMID 1846048 DOI: 10.1126/Science.1846048  0.632
1991 Rubin JS, Chan AM, Bottaro DP, Burgess WH, Taylor WG, Cech AC, Hirschfield DW, Wong J, Miki T, Finch PW. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proceedings of the National Academy of Sciences of the United States of America. 88: 415-9. PMID 1824873 DOI: 10.1073/Pnas.88.2.415  0.451
1991 Chan AM, Rubin JS, Bottaro DP, Hirschfield DW, Chedid M, Aaronson SA. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science (New York, N.Y.). 254: 1382-5. PMID 1720571 DOI: 10.1126/Science.1720571  0.628
1991 Segatto O, Lonardo F, Wexler D, Fazioli F, Pierce JH, Bottaro DP, White MF, Di Fiore PP. The juxtamembrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction. Molecular and Cellular Biology. 11: 3191-202. PMID 1674818 DOI: 10.1128/Mcb.11.6.3191  0.573
1991 AARONSON SA, BOTTARO DP, MIKI T, RON D, FINCH PW, FLEMING TP, AHN J, TAYLOR WG, RUBIN JS. Keratinocyte Growth Factor: A Fibroblast Growth Factor Family Member with Unusual Target Cell Specificity Annals of the New York Academy of Sciences. 638: 62-77. PMID 1664700 DOI: 10.1111/J.1749-6632.1991.Tb49018.X  0.611
1989 Ramponi G, Manao G, Camici G, Cappugi G, Ruggiero M, Bottaro DP. The 18 kDa cytosolic acid phosphatase from bovine liver has phosphotyrosine phosphatase activity on the autophosphorylated epidermal growth factor receptor Febs Letters. 250: 469-473. PMID 2787757 DOI: 10.1016/0014-5793(89)80778-1  0.366
1989 Molloy CJ, Bottaro DP, Fleming TP, Marshall MS, Gibbs JB, Aaronson SA. PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature. 342: 711-4. PMID 2480526 DOI: 10.1038/342711A0  0.658
1989 Bottaro DP, Bonner-Weir S, King GL. Insulin Receptor Recycling in Vascular Endothelial Cells Journal of Biological Chemistry. 264: 5916-5923. DOI: 10.1016/s0021-9258(18)83637-7  0.43
1986 Bottaro D, Shepro D, Hechtman HB. Heterogeneity of intimal and microvessel endothelial cell barriers in vitro. Microvascular Research. 32: 389-98. PMID 3796309 DOI: 10.1016/0026-2862(86)90073-7  0.531
1986 Bottaro D, Shepro D, Peterson S, Hechtman HB. Serotonin, norepinephrine, and histamine mediation of endothelial cell barrier function in vitro. Journal of Cellular Physiology. 128: 189-94. PMID 2942553 DOI: 10.1002/Jcp.1041280208  0.539
1985 Bottaro D, Shepro D, Peterson S, Hechtman HB. Serotonin, histamine, and norepinephrine mediation of endothelial and vascular smooth muscle cell movement. The American Journal of Physiology. 248: C252-7. PMID 2983565 DOI: 10.1152/Ajpcell.1985.248.3.C252  0.515
Show low-probability matches.